secret
caught
global
public
health
commun
surpris
number
laboratoryconfirm
human
case
surpass
mark
late
march
lead
declar
pandem
effort
made
toward
prevent
andor
contain
outbreak
evid
conting
measur
experiment
therapeut
must
urgent
sought
averag
cost
de
novo
drug
develop
reportedli
billion
usd
viabl
strategi
discov
potenti
candid
drug
combat
sever
acut
respiratori
syndrom
coronaviru
take
snapshot
look
strategi
drug
repurpos
also
known
drug
reprofil
reposit
promis
identifi
antivir
agent
novel
coronaviru
diseas
timecrit
fashion
also
offer
perspect
antivir
combin
doubl
hit
effect
may
offer
best
chanc
success
clinic
translat
broadspectrum
antivir
agent
bsaa
deem
safeinman
test
earli
phase
clinic
trial
tout
good
drug
repurpos
candid
andersen
et
al
recent
summar
potenti
candid
highli
access
databas
experiment
investig
approv
agent
conceptu
bsaa
take
advantag
promiscu
viral
replic
mechan
host
interact
target
two
viral
famili
follow
outbreak
decemb
exist
bsaa
rapidli
introduc
clinic
trial
span
phase
ii
though
iv
umifenovir
membran
fusion
inhibitor
target
viral
entri
lopinavirritonavir
drug
combin
target
viral
proteas
approv
indic
influenza
hiv
current
consid
differ
combin
phase
iv
clinic
trial
pneumonia
associ
clinicaltrialsgov
id
phase
iii
level
remdesivir
viral
rnadepend
rna
polymeras
inhibitor
investig
mild
moder
clinicaltrialsgov
identifi
remdesivir
activ
preclin
studi
speci
coronavirida
implic
sarscov
middl
east
respiratori
syndrom
merscov
notabl
alreadi
studi
random
control
trial
ebola
viru
diseas
demonstr
antivir
effect
phase
iii
agent
evalu
combin
therapi
viral
pneumonia
interestingli
includ
antimalari
hydroxychloroquin
base
promis
vitro
data
clinicaltrialsgov
identifi
chloroquin
addit
immunomodul
properti
shown
antivir
activ
entri
postentri
stage
infect
enhanc
antivir
activ
remdesivir
potenti
serv
synerg
bsaa
earli
stage
viral
rna
polymeras
inhibitor
favipiravir
combin
also
phase
ii
clinic
trial
novel
coronavirusassoci
pneumonia
chines
clinic
trial
registri
identifi
final
preclin
studi
ribavirin
ribonucl
analog
shown
vitro
activ
one
limit
phenotyp
screen
low
potenc
hit
compound
singl
agent
maxim
toler
dose
often
subtherapeut
new
indic
sought
one
way
circumv
issu
evalu
two
drug
act
differ
cellular
signal
pathway
involv
viral
replic
minim
redund
anoth
strategi
highthroughput
screen
compound
librari
synergist
combin
hostviru
interactom
level
emerg
reemerg
infecti
diseas
may
allow
research
narrow
spectrum
individu
antimicrobi
strategi
promis
address
oftenweak
activ
bsaa
improv
efficaci
potenti
dose
reduct
reduc
durat
cost
drug
develop
pipelin
lower
toxic
minim
emerg
secondari
resist
notion
determin
effect
drug
repurpos
strategi
whether
agent
compar
favor
virusspecif
vaccin
small
molecul
option
tradit
consid
gold
standard
modern
drug
develop
one
extrapol
experi
precis
oncolog
target
cancer
therapi
immunotherapeut
made
major
gain
cancer
broadspectrum
strategi
fundament
flaw
importantli
lack
specif
bsaa
may
becom
implic
emerg
drug
resist
virul
strain
exampl
nonstructur
protein
togeth
cofactor
coronavirida
found
repair
nucleotid
mismatch
caus
nucleosid
analog
ribavirin
thu
potenti
negat
antivir
effect
bsaa
elegantli
demonstr
ferron
et
al
sarscov
form
part
highli
flexibl
complex
multienzymat
properti
like
facilit
compens
low
fidel
replic
viabl
strategi
circumv
remark
innat
abil
coronavirida
proofread
rna
maintain
genom
integr
allow
degre
evolutionari
freedom
mutat
highthroughput
screen
come
rescu
possibl
includ
compound
affin
toward
catalyt
subunit
alloster
effect
critic
site
conserv
residu
caus
conform
chang
entir
viral
rna
repair
complex
therefor
hunt
identifi
inhibitor
viral
nucleas
drug
repurpos
compet
structurebas
design
preventativetherapeut
vaccin
small
molecul
efficaci
offtarget
toxic
turf
cov
spike
glycoprotein
use
atom
resolut
human
enzym
port
cellular
entri
determin
discoveri
hope
spur
rapid
effort
develop
vaccin
antibodi
howev
process
typic
take
decad
hinder
potenti
blunt
antigen
epitop
due
genet
drift
viru
anoth
import
dimens
quest
repurpos
drug
involv
patent
protect
issu
current
nation
andor
intern
regul
global
health
emerg
magnitud
call
bold
intern
respons
government
polit
level
therefor
regulatori
commun
must
act
fast
minim
financi
hurdl
implic
privat
industri
updat
guidelin
drug
licensur
repurpos
necessari
escap
us
vital
behindthescen
act
effort
underway
seek
new
indic
exist
compound
urgent
launch
clinic
trial
worldwid
investig
medicin
product
current
outbreak
read
within
week
month
anticip
notion
drug
repurpos
emerg
viral
diseas
scrutin
base
result
deeper
level
battl
soul
concept
new
antimicrobi
clinic
indic
one
drug
one
viru
versu
one
drug
multipl
virus
multipl
drug
one
viru
contend
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
includ
employ
consult
honoraria
stock
ownership
option
expert
testimoni
grant
patent
receiv
pend
royalti
write
assist
util
product
manuscript
work
licens
attributionnoncommercialnoderiv
unport
licens
view
copi
licens
visit
http
